EPO and anemia: This may be particularly important considering that anemia in low-risk MDS can be sometimes corrected using erythropoietin (EPO)67 or innovative agents that interfere with transforming growth factor beta superfamily inhibitors of erythropoiesis, such as the activin receptor IIA ligand trap luspatercept.67,68